Medication update.
Slagle
M A
MA
D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use*; D004304:Dosage Forms; D004347:Drug Interactions; D005260:Female; D005269:Femur / Q000187:drug effects; D006801:Humans; D008159:Lumbar Vertebrae / Q000187:drug effects; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D004304:Dosage Forms; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; C028815:salmon calcitonin; D002116:Calcitonin; D019386:Alendronate